The OSUCCC Nucleic Acid Shared Resource (NASR) provides services to cancer investigators for DNA sequencing, genotyping, DNA methylation analysis, and quantitative real-time PCR on a variety of instrumentation platforms, as well as access to equipment for nucleic acid purification, quantitative measurement and quality control of nucleic acids, and nucleic acid imaging. NASR services include comprehensive training, consultation and assistance in experimental design and expertise to develop novel methodologies and applications relevant to cancer research. The integration of several technologies into a new multifunctional OSUCCC NASR in 2004 and consolidation of the NASR on the second floor of the Biomedical Research Tower in 2007 promoted interdisciplinary activity, and enhanced cross training of staff increasing their technical skills, motivation and flexibility. These changes resulted in optimal usage of space equipment and expertise, and increased productivity and cost-effectiveness. New equipment for highthroughput gene expression analysis and next-generation sequencing technologies has expanded NASR research capabilities for both genomic and epigenomic support. Highly experienced personnel perform continuous optimization of methods and protocols with outstanding quality control which is crucial for the improvement of data quality and turnaround times. There are strong established interactions with other shared resources including the Microarray, Proteomics and Biomedical Informatics Shared Resources. The NASR maintains a website providing basic information about the policies of the facility and convenient online scheduling and secure data transfer mechanisms. The NASR's specific goals are to: 1) provide reliable, high-quality, affordable, low- and high-throughput, genomic and epigenomic support; 2) provide, optimize, develop and apply early access technologies relevant to cancer research; 3) provide and develop infrastructure and staff for new technologies for cancer research; 4) provide immediate access to data analysis and troubleshooting; 5) provide investigators with training in data analysis, experimental strategies and assistance with investigator publications. Last year's total operational expenses of $1,540,977 were covered by 46.8% charge-backs/other grants, 11.1%i CCSG support and 42.1% institutional support. In the past year, 90.9% of NASR usage was from 96 peer-reviewed funded investigators from all 6 OSUCCC research programs. Building on this solid foundation, the mandate of the OSUCCC NASR is to be an outstanding resource, to provide the best support, and to provide the highest-quality data at the lowest price in a period of rapid and profound technological advances.

Public Health Relevance

The NASR provides OSUCCC members efficient, high-quality technical and consultative services for DNA sequencing, genotyping, DNA methylation analysis, and quantitative real-time PCR, using state-of-the-art instrumentation platforms and equipment. The NASR supports proven, standard technologies and new cutting-edge next-generation sequencing and profiling technologies, resulting In high impact scientific cancer relevant accomplishments bolstered by current progress in comparative genomics, biomedical research and the human genome project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Fazio, Nicola; Buzzoni, Roberto; Baudin, Eric et al. (2016) A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. Anticancer Res 36:713-9
Eloy, Josimar O; Petrilli, Raquel; Topan, José Fernando et al. (2016) Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces 141:74-82
Byrd, John C; Flynn, Joseph M; Kipps, Thomas J et al. (2016) Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 127:79-86
Datta, Jharna; Islam, Mozaffarul; Dutta, Samidha et al. (2016) Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs. Oral Oncol 56:32-9
Wang, Hai; Agarwal, Pranay; Zhao, Shuting et al. (2016) Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 97:62-73
Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:
Rai, K; Pilarski, R; Cebulla, C M et al. (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89:285-94
Kerrigan, Kathleen; Shoben, Abigail; Otterson, Gregory (2016) Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. Clin Lung Cancer 17:523-527
DiSilvestro, David J; Melgar-Bermudez, Emiliano; Yasmeen, Rumana et al. (2016) Leptin Production by Encapsulated Adipocytes Increases Brown Fat, Decreases Resistin, and Improves Glucose Intolerance in Obese Mice. PLoS One 11:e0153198
Terakawa, Jumpei; Rocchi, Altea; Serna, Vanida A et al. (2016) FGFR2IIIb-MAPK Activity Is Required for Epithelial Cell Fate Decision in the Lower Müllerian Duct. Mol Endocrinol 30:783-95

Showing the most recent 10 out of 1929 publications